Amarin Corp Plc (AMRN)

[Dancing in the dark]

Product Description
Icosabutate is a synthetic ?-3 polyunsaturated fatty acid derived from eicosapentaenoic alcohol and 2-bromo butyric acid. It was designed to resist ß-oxidation and complex lipid incorporation and increase efficacy in fatty acid-responsive intracellular signaling systems.1,2 In a clinical trial, oral administration of icosabutate (600 mg) significantly reduced triglyceride, very low-density lipoprotein cholesterol, and Apo c-III levels in patients with very high triglyceride levels.1,2

Product Description References
1. Bays, H.E., Hallèn, J., Vige, R., et al. Icosabutate for the treatment of very high triglycerides: A placebo-controlled, randomized, double-blind, 12-week clinical trial. J.Clin.Lipidol. 10(1), 181-191 (2016).

2. Kastelein, J.J.P., Hallén, J., Vige, R., et al. Icosabutate, a structurally engineered fatty acid, improves the cardiovascular risk profile in statin-treated patients with residual hypertriglyceridemia. Cardiology 135(1), 3-12 (2016).